AIM ImmunoTech

AIM ImmunoTech Announces Launch of CEO Corner Platform

Retrieved on: 
Thursday, March 7, 2024
Corner, AIM ImmunoTech, AIM, Rintatolimod, Management

OCALA, Fla., March 07, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the launch of its CEO Corner featuring Thomas K Equels, M.S., J.D., Executive Vice Chairman, Chief Executive Officer & President of AIM ImmunoTech. The CEO Corner platform is intended to provide additional and in-depth perspective to press releases, corporate developments and development pipeline progress.

Key Points: 
  • CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress
    Access the AIM CEO Corner Here!
  • OCALA, Fla., March 07, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the launch of its CEO Corner featuring Thomas K Equels, M.S., J.D., Executive Vice Chairman, Chief Executive Officer & President of AIM ImmunoTech.
  • The CEO Corner platform is intended to provide additional and in-depth perspective to press releases, corporate developments and development pipeline progress.
  • “CEO Corner is a new way for us to connect directly with both current and potential stockholders.

AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer

Retrieved on: 
Tuesday, November 14, 2023
CTL, AIM, Safety, NYSE, Senior, Breast cancer, Celecoxib, Roswell Park, Rintatolimod, Paper, Patient, TLR3, Journal, Immunology, CKM, Pembrolizumab, AIM ImmunoTech, Science of team science, Immunotherapy, Doctor of Philosophy, Manuscript, Pharmaceutical industry, Management, Cancer, MD

OCALA, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of results from the Phase 1 study at Roswell Park Comprehensive Cancer Center in patients with metastatic triple-negative breast cancer using chemokine modulation therapy, including AIM ImmunoTech Inc.’s drug candidate Ampligen® (also known as rintatolimod), interferon α-2b and celecoxib, followed by pembrolizumab.

Key Points: 
  • OCALA, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of results from the Phase 1 study at Roswell Park Comprehensive Cancer Center in patients with metastatic triple-negative breast cancer using chemokine modulation therapy, including AIM ImmunoTech Inc.’s drug candidate Ampligen® (also known as rintatolimod), interferon α-2b and celecoxib, followed by pembrolizumab.
  • The data were published in a manuscript titled, “ Systemic Infusion of TLR3-Ligand and IFNα in Breast Cancer Patients Reprograms Local Tumor Microenvironment for Selective CTL Influx ,” in The Journal for ImmunoTherapy of Cancer.
  • The pilot study evaluated the safety of systemic CKM composed of intravenous rintatolimod (Ampligen; selective TLR3 ligand), interferon α-2b and celecoxib, and the combination’s ability to promote local CTL influx to mTNBC lesions.
  • For more information about the study, please visit ClinicalTrials.gov: NCT03599453 .

AIM ImmunoTech to Participate in the Virtual Investor Summer Spotlight Series

Retrieved on: 
Wednesday, July 5, 2023
MS, COVID-19, NYSE, AIM, Viral, Therapy, Virtual, Research, Event, AIM ImmunoTech, Disease, DSM-IV codes, Cancer, Pharmaceutical industry, Broadcasting, Vaccine

OCALA, Fla., July 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM ImmunoTech and Dr. Christopher McAleer, Scientific Officer at AIM ImmunoTech will participate in the Virtual Investor Summer Spotlight Series on Wednesday, July 12, 2023 at 11:00 AM ET.

Key Points: 
  • OCALA, Fla., July 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM ImmunoTech and Dr. Christopher McAleer, Scientific Officer at AIM ImmunoTech will participate in the Virtual Investor Summer Spotlight Series on Wednesday, July 12, 2023 at 11:00 AM ET.
  • A live video webcast of the presentation will be available on the Events page of the Company’s website ( aimimmuno.com ).
  • A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin a Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Can

Retrieved on: 
Tuesday, June 27, 2023
Pancreatic cancer, Response evaluation criteria in solid tumors, AIM, Therapy, IV, Competence, RECIST, DLT, Erasmus MC, Toxicity, Research, FOLFIRINOX, Erasmus, Doctor of Philosophy, AstraZeneca, Trial of the century, NYSE, Competent authority, MD, Patient, Central committee, Durvalumab, AIM ImmunoTech, Disease, Safety, Nootropic, Pharmaceutical industry, Rintatolimod

OCALA, Fla., June 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its TLR-3 agonist Ampligen (rintatolimod) as a novel and potentially powerful therapeutic in locally advanced pancreatic cancer (“LAPC”) and metastatic pancreatic cancer, today announced the required approvals from the Netherlands for Erasmus Medical Center (“Erasmus MC”) to begin a Phase 1b/2 study under the previously announced external sponsored collaborative clinical research agreement with AstraZeneca and Erasmus MC.

Key Points: 
  • The primary objective of the Phase 1b portion of the study is to determine the safety of combination therapy with durvalumab and Ampligen.
  • The primary objective of the Phase 2 portion of the trial is to determine the clinical benefit rate of combination therapy with durvalumab and Ampligen.
  • Patients will start with Ampligen 200mg via IV infusion twice per week for a total of 6 weeks (12 doses).
  • After two doses of Ampligen, the first dose of durvalumab 1500mg via IV infusion will be introduced in week 2.

AIM ImmunoTech to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

Retrieved on: 
Wednesday, June 14, 2023
AIM, Therapy, Maxim, Biotechnology, COVID-19, Viral, Research, Science, Charles M. Vest, AIM ImmunoTech, DSM-IV codes, Cancer, Knowledge, Conference, NYSE, Disease, Pharmaceutical industry

The exponential growth in knowledge and expertise in science and medicine continues to drive opportunities in the healthcare space.

Key Points: 
  • The exponential growth in knowledge and expertise in science and medicine continues to drive opportunities in the healthcare space.
  • These include multiple therapeutic categories and emerging technologies, which presenting companies at this year’s Maxim Healthcare Conference are focused on, and for many, that includes key data-driven events in 2023.
  • Maxim Senior Analysts will host a wide range of biotechnology and medical device companies in a series of presentations and interactive discussions with CEOs and key management.
  • Maxim will also be hosting several topical industry panels that promise to be timely and engaging.

AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast

Retrieved on: 
Monday, March 27, 2023
AIM, Therapy, COVID-19, Viral, Research, Doctor of Philosophy, DSM-IV codes, Cancer, Conference, NYSE, AIM ImmunoTech, Disease, Pharmaceutical industry

AIM ImmunoTech management will host its inaugural quarterly conference call and live audio webcast to discuss the operational and financial results on Monday, April 3rd at 8:30 AM ET.

Key Points: 
  • AIM ImmunoTech management will host its inaugural quarterly conference call and live audio webcast to discuss the operational and financial results on Monday, April 3rd at 8:30 AM ET.
  • The call will be hosted by members of AIM’s leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer.
  • Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call.
  • The live webcast will be accessible on the Events and Presentations page of the Investors section of the Company’s website, aimimmuno.com , and will be archived for 90 days following the live event.

AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center

Retrieved on: 
Tuesday, January 17, 2023
Degenerative disease, Disease, TLR3, AIM ImmunoTech, B cell, Cancer, AIM, Ovarian cancer, Nootropic, COVID-19, Erasmus, Melanoma, MD, Erasmus MC, Pancreatic cancer, Tumor microenvironment, NYSE, AstraZeneca, Immune system, Therapy, Patient, Triple-negative breast cancer, Research, PD-L1, PD-1, Pancreas, Doctor of Philosophy, Durvalumab, Pharmaceutical industry, Rintatolimod

DURIPANC Study,” in which it will use both Study Drugs provided by AstraZeneca and AIM ImmunoTech.

Key Points: 
  • DURIPANC Study,” in which it will use both Study Drugs provided by AstraZeneca and AIM ImmunoTech.
  • In the previously conducted human clinical studies, Ampligen has shown synergistic potential with PD-1 checkpoint blockade therapeutics.
  • van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, added, “PD-L1 expression levels in the malignant tumors of pancreatic cancer patients correlates to poor prognosis.
  • Additionally, there is published data from two recent clinical studies – in triple-negative breast cancer and advanced recurrent ovarian cancer – that further support Ampligen’s potential to enhance checkpoint blockade therapy efficacy.

AIM ImmunoTech Announces Corporate Governance Enhancements

Retrieved on: 
Wednesday, November 9, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Clinical Trials, Professional Football Compensation Committee, AIM, AIM ImmunoTech, NYSE, Optimism, U.S. Securities and Exchange Commission, Pancreatic cancer, Committee, ME/CFS, Annual general meeting, Food, Chronic fatigue syndrome, Knowledge, Research, Risk, Erasmus MC, Financial compensation, Association, Board, COVID-19, Degenerative disease, CFS, Special access program, Survival, FOLFIRINOX, American Association, Company, Form 10-K, Independent, Ovarian cancer, Patient, Breast cancer, Immune system, Therapy, Security (finance), Inspectorate, Cisplatin, EAP, FDA, American Association for Cancer Research, Management, Pharmaceutical industry, Rintatolimod, Facebook, Cancer

AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company) today announced the following corporate governance enhancements:

Key Points: 
  • AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company) today announced the following corporate governance enhancements:
    The Governance and Nominating Committee of the AIM Board of Directors (the Board) has initiated a process to add two directors who bring diversity and additional biotechnology commercialization experience to the Board.
  • The corporate governance enhancements we are announcing today are designed to further strengthen our Board through the addition of new independent directors with in-depth knowledge of biotechnology commercialization and diverse backgrounds, and to further align the Companys leadership with AIMs performance and the best interests of all shareholders.
  • Mitchell continued: Over the past year AIM ImmunoTech has made significant progress achieving multiple clinical and regulatory advances.
  • AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19.

AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease

Retrieved on: 
Wednesday, November 2, 2022
AIM, Inspectorate, Vaccinia, ME/CFS, Ebola, Pancreatic cancer, Chronic fatigue syndrome, Food and Drug Administration, GLOBE, Research, NYSE, Degenerative disease, COVID-19, Program, Disease, Orphan drug, Special access program, Person, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Immune system, Erasmus MC, EVD, EAP, Safety, Condition, Company, Centers for Disease Control and Prevention timeline, Cancer, FDA, Patient, Food, American, CFS, ACHES, Fever, Smallpox vaccine, CDC, Severe acute respiratory syndrome coronavirus 2, Therapy, AIM ImmunoTech, Diagnosis, Vaccine, Pharmaceutical industry, Rintatolimod

OCALA, Fla., Nov. 02, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Ampligen® (rintatolimod) for the treatment of Ebola virus disease.

Key Points: 
  • Ampligen is AIMs dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system.
  • Receiving Orphan Drug Designation for Ampligen for the treatment of Ebola from the FDA is a testament to the depth and breadth of the potential with Ampligen.
  • We continue to be encouraged by the promising results Ampligen has demonstrated to date across a number of indications where there remains significant unmet need.
  • Ebola virus disease (EVD) is a rare but severe, deadly disease causing a multitude of symptoms including fever, gastrointestinal issues, aches, and bruising.1 Previous animal studies yielded positive results utilizing Ampligen in Western Equine Encephalitis Virus, Ebola, Vaccinia Virus (which is used in the manufacture of smallpox vaccine) and SARS-CoV-1.

AIM ImmunoTech Board Files Definitive Proxy Statement and Sends Letter to Shareholders

Retrieved on: 
Monday, September 19, 2022
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, AIM ImmunoTech, SIGN, Patient, AND, National Diet of Japan Fukushima Nuclear Accident Independent Investigation Commission, CARD, Leadership, Drug development, California Department of Justice, Food, DATE, THE, Annual general meeting, Vanderbilt University School of Medicine, Company, Liver, Accounting, CKM, DNA, SEC, INTERNET, AIM, NYSE, Ovarian cancer, Association, Cancer, THOMAS, Bring Your Board!!, Board, Pathology, Fatigue, Department, Justice, Erasmus MC, Colorectal cancer, Pancreatic cancer, American Association, OR, Activism, Letter, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Breast cancer, BOARD, Board of directors, Holding company, Pharmaceutical industry, Medical device, Online gambling, Medical imaging, Management, Rintatolimod, Shareholder, American

The Board of Directors (Board) of AIM ImmunoTech Inc. (NYSE: American AIM) (AIM or the Company), today announced that the Company has filed its Definitive Proxy Statement in connection with AIMs upcoming 2022 Annual Meeting of Stockholders (the Annual Meeting), to be held on November 3, 2022, and has mailed this statement, along with a letter, to shareholders.

Key Points: 
  • The Board of Directors (Board) of AIM ImmunoTech Inc. (NYSE: American AIM) (AIM or the Company), today announced that the Company has filed its Definitive Proxy Statement in connection with AIMs upcoming 2022 Annual Meeting of Stockholders (the Annual Meeting), to be held on November 3, 2022, and has mailed this statement, along with a letter, to shareholders.
  • Thank you for your investment and your trust in AIM ImmunoTech (AIM or the Company).
  • The Board has unanimously determined that Mr. Jorgls director nominations did not comply with AIMs bylaws and are invalid.
  • THE BOARD RECOMMENDS A VOTE FOR ALL OF OUR BOARDS NOMINEES (STEWART L. APPELROUTH, THOMAS K. EQUELS AND WILLIAM M. MITCHELL)ON PROPOSAL 1 USING THE ENCLOSED WHITE PROXY CARD.